| scholarly article | Q13442814 |
| Q28362147 | A clinical role for [(123)I]MIBG myocardial scintigraphy in the distinction between dementia of the Alzheimer's-type and dementia with Lewy bodies |
| Q38759482 | Alpha-Synuclein as a Biomarker for Parkinson's Disease |
| Q64290237 | Alpha-Synuclein in Skin Nerve Fibers as a Biomarker for Alpha-Synucleinopathies |
| Q54982491 | Are dementia with Lewy bodies and Parkinson's disease dementia the same disease? |
| Q36593963 | Assessing Fluctuating Cognition in Dementia Diagnosis: Interrater Reliability of the Clinician Assessment of Fluctuation. |
| Q35624697 | Autophagy in dementias |
| Q34716867 | Benefit-risk considerations in the treatment of dementia with Lewy bodies |
| Q33896664 | Biomarkers for cognitive impairment in Parkinson disease |
| Q89738439 | Cardiac sympathetic denervation and synucleinopathy in Alzheimer's disease with brain Lewy body disease |
| Q64264303 | Cerebellar resting-state functional connectivity in Parkinson's disease and multiple system atrophy: Characterization of abnormalities and potential for differential diagnosis at the single-patient level |
| Q34577618 | Clinical-pathological agreement in dementing disorders: embracing the complexity |
| Q37597279 | Cognitive impairment and dementia in patients with Parkinson disease. |
| Q64929400 | Combined accelerometer and genetic analysis to differentiate essential tremor from Parkinson's disease. |
| Q52985613 | Correlation between neuromelanin-sensitive MR imaging and (123)I-FP-CIT SPECT in patients with parkinsonism. |
| Q33764504 | Cutaneous neuropathy in Parkinson's disease: a window into brain pathology |
| Q80690619 | Dementia with Lewy bodies |
| Q82238580 | Dementia with Lewy bodies |
| Q35474145 | Dementia with Lewy bodies according to the consensus criteria in a general population aged 75 years or older |
| Q45022206 | Dementia-current knowledge and significance for ENT specialists |
| Q52599693 | Diagnostic Criteria for Parkinson's Disease: From James Parkinson to the Concept of Prodromal Disease. |
| Q36940073 | Diagnostic errors in older patients: a systematic review of incidence and potential causes in seven prevalent diseases |
| Q33670058 | Differential Diagnosis of Parkinsonism Using Dual-Phase F-18 FP-CIT PET Imaging. |
| Q36337159 | Differential expression of galanin in the cholinergic basal forebrain of patients with Lewy body disorders |
| Q35467921 | Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study |
| Q37590848 | Epidemiology and management of essential tremor in children |
| Q48264359 | Fully automatic differential diagnosis system for dementia with Lewy bodies and Alzheimer's disease using FDG-PET and 3D-SSP. |
| Q36142447 | Higher cortical deficits influence attentional processing in dementia with Lewy bodies, relative to patients with dementia of the Alzheimer's type and controls |
| Q35469936 | How valid is the clinical diagnosis of Parkinson's disease in the community? |
| Q36752786 | Imaging non-dopaminergic function in Parkinson's disease. |
| Q92052406 | Immunotherapy Targeting Neurodegenerative Proteinopathies: α-Synucleinopathies and Tauopathies |
| Q35183572 | Inclusion of RBD improves the diagnostic classification of dementia with Lewy bodies |
| Q33879821 | Is ioflupane I123 injection diagnostically effective in patients with movement disorders and dementia? Pooled analysis of four clinical trials |
| Q35843937 | Lewy body pathology in familial Alzheimer disease: evidence for disease- and mutation-specific pathologic phenotype |
| Q33366459 | Mechanisms of hybrid oligomer formation in the pathogenesis of combined Alzheimer's and Parkinson's diseases |
| Q30480599 | Meta-analysis of the literature on diagnostic accuracy of SPECT in parkinsonian syndromes |
| Q27003314 | Neuropathological alterations in Alzheimer disease |
| Q34108175 | Neuropsychiatric aspects of Alzheimer's disease. |
| Q64764441 | Neuropsychiatric aspects of Parkinson's disease |
| Q37073141 | Olfactory bulb alpha-synucleinopathy has high specificity and sensitivity for Lewy body disorders |
| Q35982744 | On the Utility of MIBG SPECT/CT in Evaluating Cardiac Sympathetic Dysfunction in Lewy Body Diseases |
| Q35748069 | Parkin localizes to the Lewy bodies of Parkinson disease and dementia with Lewy bodies |
| Q89977694 | Parkinson's Disease in Louisiana, 1999-2012: Based on Hospital Primary Discharge Diagnoses, Incidence, and Risk in Relation to Local Agricultural Crops, Pesticides, and Aquifer Recharge |
| Q27686837 | Parkinson's disease dementia: convergence of α-synuclein, tau and amyloid-β pathologies |
| Q27007524 | Parkinsonian syndromes |
| Q35462665 | Patients with Alzheimer's disease and dementia with Lewy bodies mistaken for Creutzfeldt-Jakob disease |
| Q35476344 | Performance on the dementia rating scale in Parkinson's disease with dementia and dementia with Lewy bodies: comparison with progressive supranuclear palsy and Alzheimer's disease |
| Q25257240 | Pesticides and Parkinson's disease--is there a link? |
| Q41838690 | Phenomenology and management of cognitive and behavioral disorders in Parkinson's disease. Rise and logic of dementia in Parkinson's disease |
| Q50779352 | Predictive value of dopamine transporter SPECT imaging with [¹²³I]PE2I in patients with subtle parkinsonian symptoms. |
| Q33874572 | Prevalence of Submandibular Gland Synucleinopathy in Parkinson's Disease, Dementia with Lewy Bodies and other Lewy Body Disorders |
| Q37607924 | Primary health care providers' knowledge gaps on Parkinson's disease |
| Q41959096 | Protocol of a prospective study on the diagnostic value of transcranial duplex scanning of the substantia nigra in patients with parkinsonian symptoms |
| Q36184471 | Psychotic symptoms in Parkinson's disease. From description to etiology |
| Q50207038 | Recognizing Atypical Parkinsonisms: "Red Flags" and Therapeutic Approaches |
| Q30539712 | Role of magnetic resonance imaging, cerebrospinal fluid, and electroencephalogram in diagnosis of sporadic Creutzfeldt-Jakob disease |
| Q33670282 | Selective molecular alterations in the autophagy pathway in patients with Lewy body disease and in models of alpha-synucleinopathy |
| Q41902470 | Serotonin transporter availability in early stage Parkinson's disease and multiple system atrophy |
| Q48708067 | Sonographic discrimination of dementia with Lewy bodies and Parkinson's disease with dementia |
| Q30454798 | Specificity and sensitivity of transcranial sonography of the substantia nigra in the diagnosis of Parkinson's disease: prospective cohort study in 196 patients |
| Q36607622 | Submandibular gland biopsy for the diagnosis of Parkinson disease |
| Q89769611 | The Levodopa Response Varies in Pathologically Confirmed Parkinson's Disease: A Systematic Review |
| Q30635471 | The diagnostic accuracy of dopamine transporter SPECT imaging to detect nigrostriatal cell loss in patients with Parkinson's disease or clinically uncertain parkinsonism: a systematic review |
| Q28344297 | Transcranial magnetic stimulation studies in the Miller Fisher syndrome: evidence of corticospinal tract abnormality |
| Q64052834 | Ultrasonication-based rapid amplification of α-synuclein aggregates in cerebrospinal fluid |
Search more.